Acute megakaryoblastic leukemia natural history, complications and prognosis: Difference between revisions
(Created page with "__NOTOC__ {{Acute megakaryoblastic leukemia}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. ==Referenc...") |
No edit summary |
||
Line 2: | Line 2: | ||
{{Acute megakaryoblastic leukemia}} | {{Acute megakaryoblastic leukemia}} | ||
=== Complications: === | |||
=== '''Prognosis:''' === | |||
Apart from AMKL in Down syndrome patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity. | |||
* According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and overall survival rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.<ref name="TaubBerman2017">{{cite journal|last1=Taub|first1=Jeffrey W.|last2=Berman|first2=Jason N.|last3=Hitzler|first3=Johann K.|last4=Sorrell|first4=April D.|last5=Lacayo|first5=Norman J.|last6=Mast|first6=Kelley|last7=Head|first7=David|last8=Raimondi|first8=Susana|last9=Hirsch|first9=Betsy|last10=Ge|first10=Yubin|last11=Gerbing|first11=Robert B.|last12=Wang|first12=Yi-Cheng|last13=Alonzo|first13=Todd A.|last14=Campana|first14=Dario|last15=Coustan-Smith|first15=Elaine|last16=Mathew|first16=Prasad|last17=Gamis|first17=Alan S.|title=Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children’s Oncology Group AAML0431 trial|journal=Blood|volume=129|issue=25|year=2017|pages=3304–3313|issn=0006-4971|doi=10.1182/blood-2017-01-764324}}</ref> | |||
* Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.<ref name="QiMao2020">{{cite journal|last1=Qi|first1=Haixiao|last2=Mao|first2=Yan|last3=Cao|first3=Qian|last4=Sun|first4=Xingzhen|last5=Kuai|first5=Wenxia|last6=Song|first6=Junhong|last7=Ma|first7=Li|last8=Hong|first8=Ze|last9=Hu|first9=Jian|last10=Zhou|first10=Guoping|title=Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia|journal=Medical Science Monitor|volume=26|year=2020|issn=1643-3750|doi=10.12659/MSM.922662}}</ref> | |||
* The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 Acute Myeloid leukemia subtypes.<ref name="GiriPathak2014">{{cite journal|last1=Giri|first1=Smith|last2=Pathak|first2=Ranjan|last3=Prouet|first3=Philippe|last4=Li|first4=Bojia|last5=Martin|first5=Mike G.|title=Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia|journal=Blood|volume=124|issue=25|year=2014|pages=3833–3834|issn=0006-4971|doi=10.1182/blood-2014-09-603415}}</ref> Currently, chemotherapy and Allo-BMT are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required. | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Revision as of 18:36, 18 April 2021
Acute megakaryoblastic leukemia Microchapters |
Differentiating Acute megakaryoblastic leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Acute megakaryoblastic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Acute megakaryoblastic leukemia natural history, complications and prognosis |
FDA on Acute megakaryoblastic leukemia natural history, complications and prognosis |
CDC on Acute megakaryoblastic leukemia natural history, complications and prognosis |
Acute megakaryoblastic leukemia natural history, complications and prognosis in the news |
Blogs on Acute megakaryoblastic leukemia natural history, complications and prognosis |
Directions to Hospitals Treating Acute megakaryoblastic leukemia |
Complications:
Prognosis:
Apart from AMKL in Down syndrome patients, the prognosis of AMKL is poor. The efficacy profile of AMKL in Down syndrome patients is favorable, but it comes with a lot of treatment-related toxicity.
- According to the Children’s Oncology Group (COG) AML0431 trial results, the 5-year event-free survival and overall survival rates were 90% and 93% in 204 eligible Down syndrome with AMKL patients.[1]
- Similarly, the reported 3-year overall survival rate was 100% among 3 AMKL with Down syndrome patients while (47±12%) in non-Down syndrome patients.[2]
- The 5-year overall survival rate in AMKL was 10.6% versus 17.5% in non-M7 Acute Myeloid leukemia subtypes.[3] Currently, chemotherapy and Allo-BMT are main therapy. Treatment-related toxicity is a big challenge. To address this issue, elaborated large future clinical studies are required.
References
- ↑ Taub, Jeffrey W.; Berman, Jason N.; Hitzler, Johann K.; Sorrell, April D.; Lacayo, Norman J.; Mast, Kelley; Head, David; Raimondi, Susana; Hirsch, Betsy; Ge, Yubin; Gerbing, Robert B.; Wang, Yi-Cheng; Alonzo, Todd A.; Campana, Dario; Coustan-Smith, Elaine; Mathew, Prasad; Gamis, Alan S. (2017). "Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial". Blood. 129 (25): 3304–3313. doi:10.1182/blood-2017-01-764324. ISSN 0006-4971.
- ↑ Qi, Haixiao; Mao, Yan; Cao, Qian; Sun, Xingzhen; Kuai, Wenxia; Song, Junhong; Ma, Li; Hong, Ze; Hu, Jian; Zhou, Guoping (2020). "Clinical Characteristics and Prognosis of 27 Patients with Childhood Acute Megakaryoblastic Leukemia". Medical Science Monitor. 26. doi:10.12659/MSM.922662. ISSN 1643-3750.
- ↑ Giri, Smith; Pathak, Ranjan; Prouet, Philippe; Li, Bojia; Martin, Mike G. (2014). "Acute megakaryocytic leukemia is associated with worse outcomes than other types of acute myeloid leukemia". Blood. 124 (25): 3833–3834. doi:10.1182/blood-2014-09-603415. ISSN 0006-4971.